Tag: exercise

Jacksonville, FL, June 17, 2025 (GLOBE NEWSWIRE) -- Weight loss is a humongous challenge that many people struggle with. Lack of motivation to continue a healthy lifestyle, diet, exercise, and hormonal imbalance, pave the path for weight loss supplements for an obese person. SlimJaro emerged as a trending fruitful and healthy weight loss product. It offers the perfect blend of natural ingredients, providing sustainable, long-lasting, and safe results.

Kavango West 1X (Prospect I) rig mobilization to occur in June 2025

FORM 8.3

Execution of sustained organic growth in Canada, certain U.S. states, France, and the United Kingdom, derived from high quality pipeline of projects and growth path totaling 8 GW

FORM 8.3

Monterey, CA, June 16, 2025 (GLOBE NEWSWIRE) -- ChampionsGate Acquisition Corporation (the “Company”) (Nasdaq: CHPGU), a blank check company, today announced that, commencing on June 20, 2025, holders of the 7,475,000 units (the “Units”) sold in the Company’s initial public offering (the “Offering”) including Units sold upon a full exercise of the underwriters’ over-allotment option, may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “CHPGU.” Any underlying Class A ordinary shares and rights that are separated will trade on the NASDAQ under the symbols “CHPG” and “CHPGR,” respectively. Holders of Units will need to have their brokers contact the Company’s transfer agent, Continental Stock Transfer & Trust Company, in order to separate the holders’ Units into Class A ordinary shares and rights.

PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million. The Company anticipates that with this additional funding, PolyPid’s runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀.